[Translation] A randomized, double-blind, placebo-controlled, multi-center phase II clinical trial evaluating the efficacy and safety of oral VG081821AC tablet single drug (without taking levodopa) in the treatment of patients with early and mid-stage Parkinson's disease
本研究的主要目的为评估口服VG081821AC片单药(不伴随服用左旋多巴)治疗中国早中期帕金森病患者的有效性和安全,并评估试验组与安慰剂组MDS-UPDRS第III部分的评分与基线A2A受体表达水平的相关性
[Translation] The main purpose of this study is to evaluate the efficacy and safety of oral VG081821AC tablet monotherapy (without taking levodopa) in the treatment of Chinese patients with early and middle Parkinson's disease, and to evaluate the MDS-UPDRS part III scores of the test group and the placebo group Correlation with baseline A2A receptor expression levels